XML 59 R43.htm IDEA: XBRL DOCUMENT
v3.21.1

INVESTMENTS - RELATED PARTIES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract] |
Schedule of investments | Investments in AVLP and Alzamend Neuro, Inc. (“Alzamend”) at December 31, 2020 and 2019, are comprised of the following:
|  | December 31, |  |  | December 31, |
|  | 2020 |  |  | 2019 |
Investment in convertible promissory note of AVLP |  | $ | 11,269,136 |  |  | $ | 9,595,079 |
Short term advance in Alzamend |  |  | 750,000 |  |  |  | — |
Investment in convertible promissory note of Alzamend |  |  | 50,000 |  |  |  | — |
Accrued interest in convertible promissory notes of AVLP and Alzamend |  |  | 2,026,812 |  |  |  | 2,025,475 |
Total investment in convertible promissory note of AVLP – Gross |  |  | 14,095,948 |  |  |  | 11,620,554 |
Less: original issue discount |  |  | (3,870 | ) |  |  | — |
Less: provision for loan losses |  |  | (3,423,608 | ) |  |  | (5,079,834 | )
Total investment in convertible promissory note of AVLP and Alzamend |  |  | 10,668,470 |  |  |  | 6,540,720 |
Investment in derivative instruments of AVLP |  |  | 4,986,552 |  |  |  | 1,330,684 |
Investment in common stock of AVLP |  |  | 499,588 |  |  |  | 238,602 |
Investment in common stock and warrants of Alzamend |  |  | 653,251 |  |  |  | 558,938 |
Investment in derivative instruments and common stock of AVLP and Alzamend |  |  | 6,139,391 |  |  |  | 2,128,224 |
Total investment in AVLP and Alzamend – Net |  | $ | 16,807,861 |  |  | $ | 8,668,944 |
Investment in warrants and common stock of AVLP and Alzamend |  | $ | 6,139,391 |  |  | $ | 2,128,224 |
Investment in convertible promissory notes and advances of AVLP and Alzamend |  |  | 10,668,470 |  |  |  | 6,540,720 |
Total investment in AVLP and Alzamend – Net |  | $ | 16,807,861 |  |  | $ | 8,668,944 |
Schedule of summarizes the changes in our investments | The following table summarizes the changes in our investments in AVLP and Alzamend during the years ended December 31, 2020 and 2019:
|  |  |  |  | Investment in |  |  |  |
|  | Investment in |  |  | convertible |  |  |  |
|  | warrants and |  |  | promissory notes |  |  | Total |
|  | common stock |  |  | and advances |  |  | investment |
|  | of AVLP and |  |  | of AVLP and |  |  | in AVLP and |
|  | Alzamend |  |  | Alzamend |  |  | Alzamend – Net |
Balance at January 1, 2019 |  | $ | 3,043,499 |  |  | $ | 5,611,621 |  |  | $ | 8,655,120 |
Investment in convertible promissory notes of AVLP |  |  | — |  |  |  | 1,600,164 |  |  |  | 1,600,164 |
Investment in common stock of AVLP and Alzamend |  |  | 261,132 |  |  |  | — |  |  |  | 261,132 |
Fair value of derivative instruments issued by AVLP |  |  | 1,050,918 |  |  |  | — |  |  |  | 1,050,918 |
Unrealized loss in derivative instruments of AVLP |  |  | (1,950,875 | ) |  |  | — |  |  |  | (1,950,875 | )
Unrealized loss in common stock of AVLP and Alzamend |  |  | (276,450 | ) |  |  | — |  |  |  | (276,450 | )
Provision for loan losses |  |  | — |  |  |  | (4,000,000 | ) |  |  | (4,000,000 | )
Accretion of discount |  |  | — |  |  |  | 2,307,777 2,307,777 |  |  |  | 2,307,777 |
Accrued Interest |  |  | — |  |  |  | 1,021,158 |  |  |  | 1,021,158 |
Balance at December 31, 2019 |  | $ | 2,128,224 |  |  | $ | 6,540,720 |  |  | $ | 8,668,944 |
Investment in convertible promissory notes of AVLP |  |  | — |  |  |  | 1,330,283 |  |  |  | 1,330,283 |
Investment in convertible promissory note of Alzamend |  |  | — |  |  |  | 38,128 |  |  |  | 38,128 |
Investment in common stock of AVLP and Alzamend |  |  | 45,484 |  |  |  | — |  |  |  | 45,484 |
Investment in warrants of Alzamend |  |  | 11,872 |  |  |  | — |  |  |  | 11,872 |
Short term advance in Alzamend |  |  | — |  |  |  | 750,000 |  |  |  | 750,000 |
Fair value of derivative instruments issued by AVLP |  |  | 343,774 |  |  |  | — |  |  |  | 343,774 |
Unrealized gain in derivative instruments of AVLP |  |  | 3,312,094 |  |  |  | — |  |  |  | 3,312,094 |
Unrealized gain in common stock of AVLP and Alzamend |  |  | 297,943 |  |  |  | — |  |  |  | 297,943 |
Accretion of discount |  |  | — |  |  |  | 8,002 |  |  |  | 8,002 |
Provision for loan losses |  |  | — |  |  |  | 2,000,000 |  |  |  | 2,000,000 |
Accrued Interest |  |  | — |  |  |  | 1,337 |  |  |  | 1,337 |
Balance at December 31, 2020 |  | $ | 6,139,391 |  |  | $ | 10,668,470 |  |  | $ | 16,807,861 |

X
- Definition Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + References No definition available. + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the summary of investment holdings. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B) -URI http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010 + Details
Name: | us-gaap_SummaryInvestmentHoldingsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration